The one-year trial results confirmed that Cosentyx has long term efficacy in the treatment of psoriatic arthritis and psoriasis. Cosentyx got the approval from U.S. Food and Drug Administration for the treatment of psoriasis, in January 2015. But the Swiss drugmaker is keen to launch the drug for other related diseases, too. According to recent trial results published in The Lancet, showed promising efficacy of the injectable drug Cosentyx, produced by Novartis.
- Patients were administered with either 300mg or 150mg dose, as per the condition.
- If left untreated, complications like dysfunctional joints, heart-valve complications and eye, bowel or lung irritations may occur, triggering a serious condition.
- First from the class of IL-17A inhibitors, Cosentyx treat by targeting the protein which is linked to inflammation.